Company: BDRX
Filing Date: 2025-01-28
Form Type: 424B3
Source: 0001214659-25-001409
Chunk: 398

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-01-28
Form: 424B3
Chunk 398
---
 |        301 |     |        394 |
| Total financial assets                                    |     |      6,253 |     |      3,466 |     |     10,484 |

Financial liabilities
– amortised cost

|                                              |     | 2023 £’000 |     | 2022 £’000 |     | 2021 £’000 |
| Trade payables                               |     |        314 |     |        339 |     |        485 |
| Other payables                               |     |          7 |     |         17 |     |          5 |
| Accruals                                     |     |        857 |     |        817 |     |        546 |
| Borrowings                                   |     |        464 |     |        624 |     |        766 |
| Total financial liabilities – amortised cost |     |      1,642 |     |      1,797 |     |      1,802 |

Financial liabilities
– fair value through profit and loss – current

|                                               |     | 2023 £’000 |     | 2022 £’000 |     | 2021 £’000 |
| Equity settled derivative financial liability |     |      4,160 |     |         85 |     |        553 |

| F-60 |

19 Financial
instruments – risk management (continued)

Fair value hierarchy

The Group uses the following
hierarchy for determining and disclosing the fair value of financial instruments by valuation technique:

| · | Level 1: quoted (unadjusted) prices in active markets for identical assets and liabilities; |

| · | Level 2: other techniques for which all inputs which have a significant effect on the recorded fair value are observable, either directly 
 or indirectly; and                                                                                                                        |

| · | Level 3: techniques which use inputs that have a significant effect on the recorded fair value that are not based on observable market 
 data.                                                                                                                                  |

The fair value of the
Group’s derivative financial liability is measured on a recurring basis. The following table gives information about how the fair
value of this financial liability is determined, additional disclosure is given in note 18:

| Schedule of consolidated financial assets and liabilities at fair value |     |               |           |     |           |     |                     |     |                                                                                                               |     |                                                         |
| Financial                                                               
 liabilities                                                             |     | Fair value as 
 at            
 31/12